5 Amino 1 MQ
A selective NNMT inhibitor. 5-Amino-1MQ is studied for its role in activating AMPK pathways, promoting fat oxidation, and improving metabolic function at the cellular level.
Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How 5 Amino 1 MQ Works
5-Amino-1MQ is a potent, selective small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), designed using structure-guided binding calculations around a methylquinolinium (MQ) scaffold. NNMT is overexpressed in white adipose tissue and liver of obese individuals. By blocking NNMT, 5-Amino-1MQ prevents nicotinamide methylation, elevating intracellular NAD+ and preserving the SAM methyl donor pool — activating energy expenditure and suppressing lipogenesis without affecting food intake.
- Blocks nicotinamide methylation by NNMT with high selectivity
- Does not inhibit related SAM-dependent methyltransferases
- Does not affect NAD+ salvage pathway enzymes
- Significantly increases intracellular NAD+ levels
- Preserves SAM methyl donor pool
- Reduces intracellular 1-methylnicotinamide (MNA) accumulation
- Increases resting energy expenditure without reducing food intake
- Suppresses lipogenesis and reduces adipocyte size
- Decreases white adipose mass and plasma total cholesterol
NNMT normally consumes SAM to methylate nicotinamide into 1-methylnicotinamide (MNA), depleting both SAM and NAD+ precursors. 5-Amino-1MQ displays high passive membrane diffusion and active transport permeability, inhibiting NNMT with high selectivity (does not affect related SAM-dependent methyltransferases or NAD+ salvage pathway enzymes). This preserves SAM and increases intracellular NAD+, driving fat oxidation.
Neelakantan H et al., Biochem Pharmacol (2018): Selective NNMT inhibitors reverse high-fat diet-induced obesity in mice.
Preclinical Findings
Research Models
Clinical Data
Preclinical: 5.1% Weight Loss in 11 Days — No Food Intake Reduction
In DIO C57BL/6 mice, systemic 5-Amino-1MQ (20 mg/kg TID, 11 days) produced 5.1% body weight reduction vs. 1.4% gain in controls — without any reduction in food intake. When combined with lean diet switch (Neelakantan et al., Sci Rep 2022), treatment produced 29.3% fat mass reduction (10x greater than diet alone), rapidly normalizing body composition to age-matched lean controls. Plasma total cholesterol was also significantly lowered.
Neelakantan H et al., Biochem Pharmacol (2018); Neelakantan H et al., Sci Rep (2022).
Preclinical DIO mouse models (C57BL/6); in vitro adipocyte studies
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- No observable adverse effects reported in preclinical studies at therapeutic doses
- No impact on total food intake — weight loss is metabolism-driven, not appetite-driven
- High selectivity — does not inhibit related SAM-dependent methyltransferases or NAD+ salvage enzymes
- Treatment also elicits unique gut microbial ASV profile (Sci Rep 2022)
- No human clinical trials conducted — safety in humans has not been established
5-Amino-1MQ has not entered human clinical trials. All efficacy and safety data is preclinical (in vitro and murine models). For research use only.
About 5 Amino 1 MQ
A selective NNMT inhibitor. 5-Amino-1MQ is studied for its role in activating AMPK pathways, promoting fat oxidation, and improving metabolic function at the cellular level.
All EVO Labs Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical (Prague, est. 2013). The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
 10MG.png)
